Germany· DE-A57-fec7d634c16824d5
Neostig
A medicinal product containing neostigmine metilsulfate, registered in Germany by Carinopharm Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Neostigmine Metilsulfate
- Manufacturer
- Carinopharm Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Neostigmine metilsulfate in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBloxiverzExela Pharma Sciences, LLC
- CanadaNEOSTIGMINE METHYLSULFATE INJECTION USPMARCAN PHARMACEUTICALS INC
- BelgiumProstigmine 0.5 mg/mlViatris Healthcare
- NetherlandsNeostigminemethylsulfaat CF 0,5 mg/ml, injectievloeistofCentrafarm B.V.
- FranceNEOSTIGMINE RENAUDIN 5 mg/5 mL, solution injectableLABORATOIRE RENAUDIN
- NorwayNeostig-carinopharmCarinopharm
- PolandPolstigminumTeva Pharmaceuticals Polska Sp. z o.o.
- CzechiaSYNTOSTIGMINBB Pharma a.s., Praha
Authorised across Europe · EMA
The same active substance is authorised in 16 EEA countries. Names it is sold under:
- Austria · Neostig, Normastigmin
- Cyprus · Neostigmine Cooper
- Czechia · Syntostigmin
- Spain · Neostigmina Braun
- France · Néostigmine Renaudin, Prostigmine
- United Kingdom (Northern Ireland) · Neostigmine Methylsulfate Bp Hameln Pharma
- Greece · Neostigmine Cooper
- Croatia · Neostigmin Panpharma
- Hungary · Neostigmine Kalceks, Stigmosan
- Latvia · Neostigmine Kalceks
- Netherlands · Neostigminemethylsulfaat Cf, Prostigmin
- Poland · Polstigminum
- Portugal · Neostigmina Braun
- Romania · Miostin
- Sweden · Neostigmin Unimedic Pharma Ab
- Slovakia · Syntostigmin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/188022e0-9b8d-4b5d-9958-82f4a639a7db GET /v1/drugs/188022e0-9b8d-4b5d-9958-82f4a639a7db?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intramuscular Use ,Intravenous Use ,Subcutaneous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Neostigmine Metilsulfate",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about neostigmine metilsulfate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.